Tightening its wallet for a clinical comeback, Seres lets go of CSO and 30% of workforce
Two weeks after moving to the helm of Seres Therapeutics from the CFO office, Eric Shaff has been charged with the unenviable task of laying off his CSO alongside 30% of the biotech’s workforce in an effort to narrow the flow of cash to its microbiome clinical programs.
Matthew Henn, previously head of discovery and microbiome R&D, will take David Cook’s place as Seres cuts 30 full-time and a number of contract positions “primary related to research, manufacturing and general and administrative services.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.